Full Press Release Details
NESS ZIONA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will host an Analyst and Investor Day on Thursday, July 25, 2019 from 8:30 a.m. EST to 11:00 a.m. EST at the Maxwell Hotel in New York City.
The event will include updates regarding our clinical development programs, commercial plans, and plans for advancing new pipeline candidates into clinical studies.
The event will feature presentations by management and leading dermatologists including:
Linda Stein Gold, MD., Director of Dermatology Clinical Research at Henry Ford Health System
Jeffrey Sugarman, MD., Ph.D., Medical Director Northern California Medical Associates, Assoc. Clinical Professor, University of California, San Francisco
Mori Arkin, Chairman of The Board of Directors
Alon Seri-Levy, Ph.D., Co-Founder and Chief Executive Officer
John Vieira, U.S. Head of Commercialization
For registration and more information on the Analyst & Investor Day, please visit Solgel.troutaccess.com
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel’s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Chief Financial Officer
Source: Sol-Gel Technologies Ltd.